UNCY logo

Unicycive Therapeutics, Inc.

UNCY
Healthcare|Biotechnology|US
$3.55
+0.07 (+2.01%)
DCF Value
$1.81
Tangible Book / Share
$1.98
Cash / Share
$2.28

Ownership Breakdown

97.4%
Float
27.4M
Shares Outstanding
26.7M
Float Shares

Major Holders (40)

Combined: 258.4%

Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.

HolderType% of ClassSharesFiledFiling
Nantahala Capital Management, LLCInvestment adviser9.99%2,807,830Aug 14, 202613D/G
Vivo Opportunity, LLCOther9.99%4,856,259Aug 14, 202613D/G
Vivo Opportunity Fund Holdings, L.P.Partnership9.99%4,856,259Aug 14, 202613D/G
Daniel MackHolding company9.99%2,807,830Aug 14, 202613D/G
Wilmot B. HarkeyHolding company9.99%2,807,830Aug 14, 202613D/G
BVF Inc/IlCorporation9.99%1,417,117Aug 14, 202513D/G
Lampert Mark NIndividual9.99%1,417,117Aug 14, 202513D/G
BVF Partners L P/IlIA, PN9.99%1,417,117Aug 14, 202513D/G
BVF Partners L.P.IA, PN9.99%10,471,230Nov 14, 202413D/G
BVF Inc.Corporation9.99%10,471,230Nov 14, 202413D/G
Mark N. LampertIndividual9.99%10,471,230Nov 14, 202413D/G
Rajeev ShahHC, IN9.90%2,801,082May 15, 202613D/G
RA Capital Management, L.P.IA, PN9.90%2,801,082May 15, 202613D/G
RA Capital Healthcare Fund, L.P.Partnership9.90%2,801,082May 15, 202613D/G
Peter KolchinskyHC, IN9.90%2,801,082May 15, 202613D/G
BVF GP Holdings LLCOther9.70%1,368,958Aug 14, 202513D/G
Biotechnology Value Fund, L.P.Partnership6.20%6,210,638Nov 14, 202413D/G
BVF I GP LLCOther5.70%777,308Aug 14, 202513D/G
Biotechnology Value Fund L PPartnership5.70%777,308Aug 14, 202513D/G
BlackRock, Inc.Holding company5.30%1,413,381Jul 30, 202613D/G
Logos Global Management LPIA, PN4.90%5,078,927Nov 14, 202413D/G
Logos Global Management GP LLCHC, OO4.90%5,078,927Nov 14, 202413D/G
Arsani WilliamHC, IN4.90%5,078,927Nov 14, 202413D/G
Logos Opportunities Fund III LPPartnership4.90%5,078,927Nov 14, 202413D/G
Logos Opportunities II GP, LLCOther4.90%5,078,927Nov 14, 202413D/G
Walleye Capital LLCInvestment adviser4.82%5,000,000Feb 6, 202513D/G
Octagon Capital Advisors LPIA, PN4.70%1,000,000Feb 10, 202613D/G
Ting JiaHC, IN4.70%1,000,000Feb 10, 202613D/G
Ms. Lillian NordahlHC, IN4.51%796,558Nov 14, 202513D/G
Dr. Jeffrey R. Jay, M.D.HC, IN4.51%796,558Nov 14, 202513D/G
Great Point Partners, LLCIA, OO4.51%796,558Nov 14, 202513D/G
BVF II GP LLCOther4.40%591,650Aug 14, 202513D/G
Biotechnology Value Fund II LPPartnership4.40%591,650Aug 14, 202513D/G
Biotechnology Value Fund II, L.P.Partnership3.80%3,709,000Nov 14, 202413D/G
Octagon Investments Master Fund LPPN, OO3.00%650,000Feb 10, 202613D/G
Nantahala Capital Partners Limited PartnershipPartnership2.76%3,009,021Dec 20, 202413D/G
Octagon Private Opportunities Fund II LPPN, OO2.00%350,000Nov 14, 202513D/G
Octagon Biotech Opportunities Fund I LPPN, OO1.70%350,000Feb 10, 202613D/G
Israel A. EnglanderIndividual1.00%271,456Jul 8, 202613D/G
Millennium Management LLCOther1.00%271,456Jul 8, 202613D/G

Insider Trades (95)

Last 4 quarters: 4,201,032 acquired · 3,885.21 disposed
InsiderPositionDateTypeSharesPriceValueFiling
Manning MeredithdirectorOct 28, 2026AWARD27,000$3.76$101.5KForm 4
Manning MeredithdirectorOct 28, 2026AWARD3,350——Form 4
Manning Meredithdirector: Oct 1, 2026OTHER0——Form 4
Kenkare-Mitra SaradirectorMay 14, 2026AWARD47,941——Form 4
Laumas SandeepdirectorMay 14, 2026AWARD47,941——Form 4
Gupta Shalabh K.director, officer: CEOMay 14, 2026AWARD762,200——Form 4
Kenkare-Mitra SaradirectorMay 14, 2026AWARD42,100——Form 4
Kenkare-Mitra SaradirectorMay 14, 2026AWARD84,200——Form 4
Jermasek DouglasEVP, Corporate StrategyMay 14, 2026AWARD169,500——Form 4
Gupta PramodEVP, Pharmaceuticals and BDMay 14, 2026AWARD169,500——Form 4
Townsend JohnCFOMay 14, 2026AWARD169,500——Form 4
Laumas SandeepdirectorMay 14, 2026AWARD42,100——Form 4
Laumas SandeepdirectorMay 14, 2026AWARD84,200——Form 4
Aggarwal GauravdirectorAug 25, 2025CONVERSION652,900——Form 4
Aggarwal GauravdirectorAug 25, 2025DISPOSED3,199.21$4.90$15.7KForm 4
Aggarwal GauravdirectorJul 28, 2025AWARD21,200$4.71$99.9KForm 4
Laumas SandeepdirectorJul 28, 2025AWARD21,200$4.71$99.9KForm 4
Kenkare-Mitra SaradirectorJul 28, 2025AWARD21,200$4.71$99.9KForm 4
Gupta Shalabh K.director, officer: CEOJul 28, 2025AWARD325,000$4.71$1.5MForm 4
Townsend JohnChief Financial OfficerJul 28, 2025AWARD10,000$4.71$47.1KForm 4
Gupta PramodEVP, Pharmaceuticals and BDJul 28, 2025AWARD90,000$4.71$423.9KForm 4
Jermasek DouglasEVP of Corporate StrategyJul 28, 2025AWARD10,000$4.71$47.1KForm 4
Aggarwal GauravdirectorFeb 18, 2025CONVERSION1,400,000——Form 4
Aggarwal GauravdirectorFeb 18, 2025DISPOSED686$0.49$336.14Form 4
Aggarwal GauravdirectorOct 9, 2024CONVERSION5,500,000$1000.00$5.50BForm 4
Aggarwal GauravdirectorOct 9, 2024DISPOSED2,695$0.49$1.3KForm 4
Townsend JohnChief Financial OfficerAug 12, 2024AWARD40,256$0.34$13.7KForm 4
Gupta PramodEVP, Pharmaceuticals and BDAug 12, 2024AWARD81,750$0.34$27.8KForm 4
Jermasek DouglasEVP of Corporate StrategyAug 12, 2024AWARD81,750$0.34$27.8KForm 4
Gupta Shalabh K.director, officer: CEOAug 12, 2024AWARD232,868$0.34$79.2KForm 4
Townsend JohnChief Financial OfficerApr 15, 2024AWARD228,119$1.14$260.1KForm 4
Jermasek DouglasEVP of Corporate StrategyApr 15, 2024AWARD463,250$1.14$528.1KForm 4
Gupta PramodEVP, Pharmaceuticals and BDApr 15, 2024AWARD463,250$1.14$528.1KForm 4
Gupta Shalabh K.director, 10 percent owner, officer: CEOApr 15, 2024AWARD1,319,583$1.14$1.5MForm 4
Laumas SandeepdirectorSep 5, 2023AWARD189,236$0.76$143.8KForm 4
Kenkare-Mitra SaradirectorSep 5, 2023AWARD180,000$0.76$136.8KForm 4
Ryan John LdirectorSep 5, 2023AWARD112,147$0.76$85.2KForm 4
Aggarwal GauravdirectorSep 5, 2023AWARD180,000$0.76$136.8KForm 4
Kenkare-Mitra Saradirector: Sep 5, 2023OTHER0——Form 4
Gupta PramodEVP, Pharmaceuticals and BDAug 28, 2023AWARD1,355,000$0.75$1.0MForm 4
Gupta Shalabh K.director, officer: CEOAug 28, 2023AWARD4,684,775$0.75$3.5MForm 4
Townsend JohnChief Financial OfficerAug 28, 2023AWARD570,329$0.75$427.7KForm 4
Jermasek DouglasEVP of Corporate StrategyAug 28, 2023AWARD1,355,000$0.75$1.0MForm 4
Aggarwal GauravdirectorJul 11, 2023CONVERSION18,621,655$0.74$13.8MForm 4
Aggarwal GauravdirectorJul 11, 2023CONVERSION13,429,000——Form 4
Aggarwal GauravdirectorJul 11, 2023CONVERSION12,802,388$0.54$6.9MForm 4
Aggarwal GauravdirectorJul 11, 2023CONVERSION11,638,534$0.59$6.9MForm 4
Aggarwal GauravdirectorJul 11, 2023CONVERSION3,470,152——Form 4
Aggarwal GauravdirectorJul 11, 2023CONVERSION8,077$0.49$4.0KForm 4
Jermasek DouglasEVP of Corporate StrategyJul 11, 2023OPTION EX.104,612$0.49$51.3KForm 4
Jermasek DouglasEVP of Corporate StrategyJul 11, 2023OPTION EX.115,275$0.74$85.3KForm 4
Jermasek DouglasEVP of Corporate StrategyJul 11, 2023OPTION EX.79,252$0.54$42.8KForm 4
Jermasek DouglasEVP of Corporate StrategyJul 11, 2023OPTION EX.72,047$0.59$42.5KForm 4
Jermasek DouglasEVP of Corporate StrategyJul 11, 2023OPTION EX.50$0.49$24.50Form 4
Gupta PramodEVP, Pharmaceuticals and BDJul 11, 2023OPTION EX.46,110$0.74$34.1KForm 4
Gupta PramodEVP, Pharmaceuticals and BDJul 11, 2023OPTION EX.41,845$0.49$20.5KForm 4
Gupta PramodEVP, Pharmaceuticals and BDJul 11, 2023OPTION EX.31,700$0.54$17.1KForm 4
Gupta PramodEVP, Pharmaceuticals and BDJul 11, 2023OPTION EX.28,818$0.59$17.0KForm 4
Gupta PramodEVP, Pharmaceuticals and BDJul 11, 2023OPTION EX.20$0.49$9.80Form 4
Gupta Shalabh K.director, officer: CEOJul 11, 2023OPTION EX.104,612$0.49$51.3KForm 4
Gupta Shalabh K.director, officer: CEOJul 11, 2023OPTION EX.115,275$0.74$85.3KForm 4
Gupta Shalabh K.director, officer: CEOJul 11, 2023OPTION EX.79,252$0.54$42.8KForm 4
Gupta Shalabh K.director, officer: CEOJul 11, 2023OPTION EX.72,047$0.59$42.5KForm 4
Gupta Shalabh K.director, officer: CEOJul 11, 2023OPTION EX.50$0.49$24.50Form 4
Schiller Brigittedirector: Jul 15, 2022OTHER0——Form 4
Aggarwal GauravdirectorMar 8, 2023AWARD8,077$0.49$4.0KForm 4
Gupta Shalabh K.director, officer: CEOMar 8, 2023AWARD50$0.49$24.66Form 4
Gupta PramodEVP, Pharmaceuticals and BDMar 8, 2023AWARD20$0.49$9.87Form 4
Jermasek DouglasEVP of Corporate StrategyMar 8, 2023AWARD50$0.49$24.66Form 4
Aggarwal Gauravdirector: Mar 8, 2023OTHER0——Form 4
Townsend JohnChief Financial OfficerNov 21, 2022AWARD35,000——Form 4
Jermasek DouglasEVP of Corporate StrategyNov 21, 2022AWARD55,000——Form 4
Gupta Shalabh K.CEONov 21, 2022AWARD86,000——Form 4
Gupta PramodEVP, Pharmaceuticals and BDNov 21, 2022AWARD28,000——Form 4
Jermasek DouglasdirectorNov 18, 2022DISPOSED100,000$2.56$256.0KForm 4
Jermasek DouglasdirectorNov 18, 2022DISPOSED0——Form 4
Schiller Brigittedirector: Jul 15, 2022OPTION EX.26,738——Form 4
Schiller Brigittedirector: May 16, 2022BUY15,000$0.82$12.4KForm 4
Gupta Shalabh K.director, officer: CEOJul 15, 2021AWARD116,279$5.00$581.4KForm 4
Gupta PramodEVP, Pharmaceuticals and BDJul 15, 2021AWARD34,884$5.00$174.4KForm 4
Townsend JohnChief Financial OfficerJul 15, 2021AWARD18,605$5.00$93.0KForm 4
Ryan John LdirectorJul 12, 2021DISPOSED0——Form 4
Ryan John LdirectorJul 12, 2021DISPOSED11,628$0.01$116.28Form 4
Gupta Shalabh K.director, officer: CEO & PresidentJul 12, 2021DISPOSED0——Form 4
Gupta Shalabh K.director, officer: CEO & PresidentJul 12, 2021OTHER0——Form 4
Gupta Shalabh K.director, officer: CEO & PresidentJul 12, 2021OTHER0——Form 4
Gupta Shalabh K.director, officer: CEO & PresidentJul 12, 2021OTHER0——Form 4
Gupta Shalabh K.director, officer: CEO & PresidentJul 12, 2021DISPOSED101,744$0.01$1.0KForm 4
Schiller Brigittedirector: Jul 12, 2021OTHER0——Form 4
Laumas SandeepdirectorJul 12, 2021OTHER0——Form 4
Laumas SandeepdirectorJul 12, 2021DISPOSED0——Form 4
Laumas SandeepdirectorJul 12, 2021DISPOSED11,628$0.01$116.28Form 4
Gupta PramodEVP, Pharma and Business OpsJul 12, 2021DISPOSED58,140$3.27$190.1KForm 4
Gupta PramodEVP, Pharma and Business OpsJul 12, 2021DISPOSED23,256$7.01$163.0KForm 4
Townsend JohnChief Financial OfficerJul 12, 2021DISPOSED23,256$7.01$163.0KForm 4